FDA Approves Journavx, First Non-Opioid Painkiller in Over Two Decades

The new drug offers an alternative to opioids for acute pain management with fewer risks of addiction and overdose.

Journavx, also known as suzetrigine, has been approved by the FDA as a non-opioid painkiller for short-term acute pain relief in adults.
The drug targets NaV1.8 sodium channels on pain-sensing neurons, providing pain relief without the sedation or dependency risks associated with opioids.
Clinical trials demonstrated comparable effectiveness to opioids like Vicodin, with faster action and fewer side effects such as nausea and drowsiness.
Experts highlight its potential to reduce opioid prescriptions and related addiction risks, though it is not yet approved for chronic pain and costs $15.50 per pill.
Medical professionals and advocates view Journavx as a public health milestone but emphasize the importance of affordability and insurance coverage for accessibility.